Active Not Recruiting PHASE2 INTERVENTIONAL 5-arm NCT05458297

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (waveLINE-006)

Sponsor: Merck Sharp & Dohme LLC

Conditions Chronic Lymphocytic Leukemia Follicular Lymphoma Mantle Cell Lymphoma Richter Transformation Lymphoma

Interventions Nemtabrutinib Zilovertamab vedotin

Updated 40 times since 2022 Last updated: Mar 10, 2026 Started: Jul 21, 2022 Primary completion: May 17, 2029 Completion: May 17, 2029

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Chronic Lymphocytic Leukemia and Follicular Lymphoma, this trial is ongoing. The trial is conducted by Merck Sharp & Dohme LLC and has accumulated 40 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

40 versions recorded

Mar 2026 — Present [monthly]

Active Not Recruiting PHASE2

Status: Recruiting → Active Not Recruiting
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE2
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE2
Dec 2025 — Jan 2026 [monthly]

Recruiting PHASE2
Nov 2025 — Dec 2025 [monthly]

Recruiting PHASE2

▶ Show 35 earlier versions

Oct 2025 — Nov 2025 [monthly]

Recruiting PHASE2
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE2
Aug 2025 — Sep 2025 [monthly]

Recruiting PHASE2
Jul 2025 — Aug 2025 [monthly]

Recruiting PHASE2
Jun 2025 — Jul 2025 [monthly]

Recruiting PHASE2
May 2025 — Jun 2025 [monthly]

Recruiting PHASE2
Mar 2025 — May 2025 [monthly]

Recruiting PHASE2
Jan 2025 — Mar 2025 [monthly]

Recruiting PHASE2
Dec 2024 — Jan 2025 [monthly]

Recruiting PHASE2
Nov 2024 — Dec 2024 [monthly]

Recruiting PHASE2
Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE2
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE2
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE2
Jun 2024 — Jul 2024 [monthly]

Recruiting PHASE2
May 2024 — Jun 2024 [monthly]

Recruiting PHASE2
Apr 2024 — May 2024 [monthly]

Recruiting PHASE2
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE2
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE2
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE2
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE2
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE2
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE2
Sep 2023 — Oct 2023 [monthly]

Recruiting PHASE2
Aug 2023 — Sep 2023 [monthly]

Recruiting PHASE2
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE2
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE2
May 2023 — Jun 2023 [monthly]

Recruiting PHASE2
Apr 2023 — May 2023 [monthly]

Recruiting PHASE2
Mar 2023 — Apr 2023 [monthly]

Recruiting PHASE2
Feb 2023 — Mar 2023 [monthly]

Recruiting PHASE2
Jan 2023 — Feb 2023 [monthly]

Recruiting PHASE2
Dec 2022 — Jan 2023 [monthly]

Recruiting PHASE2
Nov 2022 — Dec 2022 [monthly]

Recruiting PHASE2
Sep 2022 — Nov 2022 [monthly]

Recruiting PHASE2

First recorded

Jul 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Merck Sharp & Dohme LLC

Data source: Merck Sharp & Dohme LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Afula, Israel , Alessandria, Italy , Anchorage, United States , Ankara, Turkey (Türkiye) , Ann Arbor, United States , Arequipa, Peru , Aurora, United States , Baltimore, United States , Barcelona, Spain , Beersheba, Israel and 87 more locations